On the podcast, Biocon Executive Chairperson Kiran Mazumdar-Shaw said a wealthy friend sold her property to afford a ₹2.5 lakh-per-dose cancer therapy and later died. "Why are we paying so much?" she asked. That grief pushed Biocon into developing biosimilars, copies of complex biologic drugs, to make cancer care more affordable.